Patents by Inventor Frantisek Hubalek

Frantisek Hubalek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
    Publication number: 20240425837
    Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
    Type: Application
    Filed: August 21, 2024
    Publication date: December 26, 2024
    Inventors: Andreas Vegge, Daniele Granata, Eva Johansson, Jais Rose Bjelke, Jacob Lund, Philip Jones Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
  • Insulin analogues and uses thereof
    Patent number: 12152063
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: October 6, 2022
    Date of Patent: November 26, 2024
    Assignee: Novo Nordisk A/S
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • Insulin analogues and uses thereof
    Patent number: 12122818
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: December 15, 2023
    Date of Patent: October 22, 2024
    Assignee: Novo Nordisk A/S
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • Highly potent ISVD compounds capable of substituting for FVIII(A)
    Patent number: 12098400
    Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
    Type: Grant
    Filed: July 7, 2023
    Date of Patent: September 24, 2024
    Assignee: Novo Nordisk A/S
    Inventors: Andreas Vegge, Daniele Granata, Jais Rose Bjelke, Jacob Lund, Philip Jonas Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
  • NOVEL INSULIN ANALOGUES AND USES THEREOF
    Publication number: 20240141011
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: December 15, 2023
    Publication date: May 2, 2024
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
    Publication number: 20240067944
    Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
    Type: Application
    Filed: July 7, 2023
    Publication date: February 29, 2024
    Applicant: Novo Nordisk A/S
    Inventors: Andreas Vegge, Daniele Granata, Eva Johansson, Jais Rose Bjelke, Jacob Lund, Philip Jonas Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
  • NOVEL INSULIN ANALOGUES AND USES THEREOF
    Publication number: 20230192801
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: October 6, 2022
    Publication date: June 22, 2023
    Applicants: Novo Nordisk A/S, Novo Nordisk A/S
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • Insulin analogues and uses thereof
    Patent number: 11498951
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: November 15, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • Insulins with polar recombinant extensions
    Patent number: 11208452
    Abstract: The present invention relates to novel insulins or insulins analogues that are extended with predominantly sequences of polar amino acid residues in order to improve the half-life and stability of the drug substance. The invention also provides pharmaceutical compositions comprising such drug substances, and relates to the use of such drug substances for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: December 28, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Tine Nygaard Vinther, Frantisek Hubalek, Ingrid Pettersson
  • Insulin compositions and method of making a composition
    Patent number: 11167035
    Abstract: The invention is related to insulin compositions with a high content of zinc atoms per six molecules of acylated insulin. The insulin is an acylated insulin and may be mixed with a further insulin analogue such as the rapid acting insulin Asp B28 human insulin.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: November 9, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Svend Havelund, Frantisek Hubalek, Helle Birk Olsen, Ib Jonassen, Thomas Hoeg-Jensen, Anne Plum, Ulla Ribel-Madsen
  • NOVEL INSULIN ANALOGUES AND USES THEREOF
    Publication number: 20210179685
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: December 10, 2020
    Publication date: June 17, 2021
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen
  • INSULINS WITH POLAR RECOMBINANT EXTENSIONS
    Publication number: 20180291076
    Abstract: The present invention relates to novel insulins or insulins analogues that are extended with predominantly sequences of polar amino acid residues in order to improve the half-life and stability of the drug substance. The invention also provides pharmaceutical compositions comprising such drug substances, and relates to the use of such drug substances for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: June 2, 2016
    Publication date: October 11, 2018
    Inventors: Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Tine Nygaard Vinther, Frantisek Hubalek, Ingrid Pettersson
  • Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery
    Publication number: 20170258711
    Abstract: The present invention relates to fatty acid acylated amino acids (FA-Daa's) acting as permeation enhancers for oral delivery of therapeutic macromolecules such as peptides and pharmaceutical compositions comprising such FA-Daa's.
    Type: Application
    Filed: May 30, 2017
    Publication date: September 14, 2017
    Inventors: Frantisek Hubalek, Florian Anders Foeger, Abdallah Makhlof
  • Insulin derivatives containing additional disulfide bonds
    Patent number: 9512195
    Abstract: The present invention is related to insulin derivatives containing additional disulfide bonds and methods of making such.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: December 6, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Frantisek Hubalek, Thomas Boerglum Kjeldsen, Svend Ludvigsen
  • Method for Making Mature Insulin Polypeptides
    Publication number: 20160115216
    Abstract: This invention relates to an improved method for making mature human insulin or an analogue thereof by cultivating fungi cell comprising a DNA sequence encoding a precursor for human insulin or an analogue thereof, which precursor comprises a small connecting peptide.
    Type: Application
    Filed: June 6, 2014
    Publication date: April 28, 2016
    Inventors: Frantisek Hubalek, Annette F. Pettersson, Thomas B. Kjeldsen, Asser S. Andersen
  • Novel Oral Pharmaceutical Composition for Treatment of Diabetes
    Publication number: 20160106814
    Abstract: The invention provides improved solid oral pharmaceutical compositions comprising an insulin peptide or GLP-1 peptide and methods of producing such.
    Type: Application
    Filed: May 30, 2014
    Publication date: April 21, 2016
    Inventors: Salka Elboel Rasmussen, Frantisek Hubalek, Andreanne Bouchard, Abdallah Makhlof, Betty Lomstein Pedersen
  • Protease-stabilized insulin analogues
    Patent number: 9260502
    Abstract: The present invention relates to novel insulin analogs comprising mutations at position A14 in the A chain and at positions B27, B28, B29 and B30 in the B chain and exhibiting resistance towards protease; a method for the preparation of such insulin analogs; insulin preparations containing the insulin analogs of the invention; and, a method of treating diabetes mellitus using these insulin analogs.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: February 16, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Peter Kresten Nielsen, Frantisek Hubalek, Inger Lautrup-Larsen, Per Balschmidt, Svend Ludvigsen, Thomas Børglum Kjeldsen
  • Human insulin analogues and derivatives comprising cysteine substitutions
    Patent number: 9187547
    Abstract: The present invention relates to human insulin analogues containing a substituting cysteine, to human insulin derivatives containing a PEGylated substituting cysteine and methods of making such. The compounds of the invention may be useful for the treatment of diabetes.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: November 17, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Tine Nygaard Vinther, Thomas Boerglum Kjeldsen, Frantisek Hubalek, Knud J. Jensen
  • FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY
    Publication number: 20150273069
    Abstract: The present invention relates to oral pharmaceutical compositions comprising a GLP-1 peptide and a fatty acid acylated amino acid and use thereof.
    Type: Application
    Filed: October 16, 2013
    Publication date: October 1, 2015
    Inventors: Simon Bjerregaard, Florian Foeger, Stephen Buckley, Frantisek Hubalek
  • Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery
    Publication number: 20150265710
    Abstract: The present invention relates to fatty acid acylated amino acids (FA-Daa's) acting as permeation enhancers for oral delivery of therapeutic macromolecules such as peptides and pharmaceutical compositions comprising such FA-Daa's.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 24, 2015
    Inventors: Frantisek Hubalek, Florian Anders Foeger, Abdallah Makhlof